J&J's IMAAVY Shows Sustained Efficacy in Long-Term MG Trial
Event summary
- Johnson & Johnson’s IMAAVY (nipocalimab-aahu) demonstrated sustained clinical improvements and IgG reductions in generalized myasthenia gravis (gMG) patients through 120 weeks of follow-up in the Vivacity-MG3 study.
- Patients achieving sustained minimal symptom expression (MSE) experienced greater quality of life improvements compared to those with transient MSE.
- The EPIC study, a head-to-head trial of IMAAVY versus efgartigimod, is now enrolling participants.
- Data presented at the American Academy of Neurology (AAN) 2026 meeting indicates 57% of patients reached low doses of corticosteroids during the open-label extension (OLE).
The big picture
The long-term data for IMAAVY reinforces the growing trend towards targeted therapies for autoimmune diseases, particularly those requiring chronic management. The ongoing EPIC trial represents a significant test of J&J’s strategy to dominate the FcRn blocker market, which is estimated to be a multi-billion dollar opportunity. The focus on patient-centric outcomes, such as MSE, highlights the increasing importance of quality-of-life measures in drug development and approval.
What we're watching
- Competitive Landscape
- The EPIC trial's results will be critical in determining whether IMAAVY can maintain its competitive advantage against efgartigimod in the FcRn blocker market.
- Adoption Rate
- The pace at which physicians adopt IMAAVY for long-term management of gMG will depend on the continued demonstration of sustained efficacy and safety in real-world settings.
- Regulatory Pathway
- The FDA's and EMA's assessment of the long-term data and EPIC results will influence the potential for expanded indications and label updates for IMAAVY.
Related topics